News Related to Mechanistic Target of Rapamycin Complex 1

Related coverage linked through entity extraction aliases.

FDA Accepts Celcuity's NDA for Gedatolisib in Advanced Breast Cancer with July 2026 Goal Date

Nov 17, 2025

The FDA has accepted Celcuity's New Drug Application for gedatolisib in HR+/HER2-/PIK3CA wild-type advanced breast cancer, granting Priority Review with a PDUFA goal date of July 17, 2026.

Drug Hunter Highlights Notable Small Molecules from July Through December 2025

Aug 15, 2025

Drug Hunter's monthly molecule selections from July through December 2025 feature innovative small molecule candidates targeting pain, epilepsy, cancer, infectious diseases, and metabolic disorders, including non-opioid pain agents and precision therapies for rare conditions.